Skip to main content
Log in

Mutant presenilin 2 causes abnormality in the brain lipid profile in the development of Alzheimer’s disease

  • Articles
  • Drug Development
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Mutation in the presenilin 2 (PS2mt) is known to be one of factors involved in the development of Alzheimer’s disease (AD). It was recently revealed that an abnormality of lipid metabolism is a phenomenon occurring in AD. Therefore, the aim of this study was to investigate the potential relationship between the mutation of PS2 and alterations of the lipid profile within the brain. The results showed there increases in the levels of cholesterol, low density lipoprotein and triglyceride, but a decrease in the level of high density lipoprotein in brain tissues expressing mutant PS2. These findings indicated that PS2mt is involved in the abnormalities of the lipid profile, which could cause or result in the development of AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bums, M., Gaynor, K., and Olm, V., Presenilin redistribution associated with aberrant cholesterol transport enhances bamyloid production in vivo.J. Neurosci., 23, 5645–5649 (2003).

    Google Scholar 

  • Buxbaum, J. D., Geoghagan, N. S., and Friedhoff, L. T., Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide.J. Alzheimers Dis., 3, 221–229 (2001).

    PubMed  CAS  Google Scholar 

  • Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., Troncoso, J. C., and Mattson, M. P., Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease.Proc Natl. Acad. Sci. U.S.A., 101, 2070–2075 (2004).

    Article  PubMed  CAS  Google Scholar 

  • De Samo, P., Lesort, M., Bijur, G. N., Johnson, G. V., and Jope, R. S., Cholinergic- and stress-induced signaling activities in cells overexpressing wild-type and mutant presenilin-1.Brain Res., 903, 226–230 (2001).

    Article  Google Scholar 

  • Deng, G., Pike, C. J., and Cotman, C. W., Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells.FEBS Lett., 397, 50–54 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Diebold, K., Michel, G., Schweizer, J., Diebold-Dorsam, M., Fiehn, W., and Kohl, B., Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?Pharmacopsychiatry, 31, 60–67 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Ehehalt, R., Keller, P., and Haass, C., Amyloidogenic processing of the Alzheimer b-amyloid precursor protein depends on lipid rafts.J. Cell Biol., 60, 113–123 (2003).

    Article  Google Scholar 

  • Fassbender, K., Simons, M., and Bergmann, C., Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Ab42 and Ab40in vitro and in vivo.Proc. Natl. Acad Sci. USA, 98, 5856–5861 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Galbete, J. L., Martin, T. R., Peressini, E., Modena, P., Bianchi, R., and Forloni, G., Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway.Biochem. J., 348, 307–313 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Hwang, D. Y., Chae, K. R., Kang, T. S., Hwang, J. H., Lim, C. H., Kang, H. K., Goo, J. S., Lee, M. R., Lim, H. J., Min, S. H., Cho, J. Y., Hong, J. T., Song, C. W., Paik, S. G., Cho, J. S., and Kim, Y. K., Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer’s disease.FASEB J., 16, 805–813 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Ignatius, M. J., Gebicke-Harter, P. J., and Skene, J. H., Expression of apolipoprotein E during nerve degeneration and regeneration.Proc. Natl. Acad. Sci. U.S.A., 83, 1125–1129 (1986).

    Article  PubMed  CAS  Google Scholar 

  • Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Amim, C. A., Martin-Rehrmann, M., Manelli, A., LaDu, M. J., Hyman, B. T., and Rebeck, G. W., Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein.J. Neurochem., 90, 1132–1143 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Janicki, S. and Monteiro, M. J., Increased apoptosis arising from increased expression of the Alzheimer’s diseaseassociated presenilin-2 mutation (N1411).J. Cell Biol., 139, 485–495 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Jick, H., Zomberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A., Statins and the risk of dementia.Lancet, 356, 1627–1631 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Koudinov, A. R., Berezov, T. T., and Koudinov, N. V., The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer’s and normal aging cerebrospinal fluid: implication for brain cholesterol pathology?Neurosci. Lett., 314, 115–118 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Koudinov, A. R., Berezov, T. T., and Kumar, A., Alzheimer’s amyloid b interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids.Clin. Chim. Acta., 270, 75–84 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Lee, S. Y., Hwang, D. Y., Kim, Y. K., Lee, J. W., Shin, I. C., Oh, K. W., Lee, M. K., Lim, J. S., Yoon, do. Y., Hwang, S. J., and Hong, J. T., PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release.FASEB J., 20, 151–153 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Michikawa, M., Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer’s disease?J. Neurosci. Res., 72, 141–146 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Mori, M., Nakagami, H., Morishita, R., Mitsuda, N., Yamamoto, K., Yoshimura, S., Ohkubo, N., Sato, N., Ogihara, T., and Kaneda, Y., N141l mutant presenilin-2 gene enhances neuronal cell death and decreases bcl-2 expression.Life Sci., 70, 2567–2580 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Pappolla, M. A., Bryant-Thomas, T. K., and Herbert, D., Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology.Neurology, 61, 199–205 (2003).

    PubMed  CAS  Google Scholar 

  • Refolo, L. M., Pappolla, M. A., and La Francois, J., A cholesterol-lowering drug reduces b-amyloid pathology in a transgenic mouse model of Alzheimer’s disease.Neurobiol. Dis., 8, 890–899 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Refolo, L. M., Malester, B., La Francois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., Duff, K., and Pappolla, M. A., Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model.Neurobiol. Dis., 7, 321–331 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., and Hartmann, T., Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells.J. Neurosci., 22, 1679–1689 (2002).

    PubMed  CAS  Google Scholar 

  • Sawamura, N., Morishima-Kawashima, M., Waki, H., Kobayashi, K., Kuramochi, T., Frosch, M. P., Ding, K., Ito, M., Kim, T. W., Tanzi, R. E., Oyama, F., Tabira, T., Ando, S., and Ihara, Y., Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin.J. Biol. Chem., 275, 27901–27908 (2000).

    PubMed  CAS  Google Scholar 

  • Shie, F. S., Jin, L. W., and Cook, D. G., Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice.Neuroreport, 213, 455–459 (2002).

    Article  Google Scholar 

  • Simons, K. and Ikonen, E., How cells handle cholesterol.Science, 290, 1721–1726 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Subasinghe, S., Unabia, S., Barrow, C. J., Mok, S. S., Aguilar, M. I., and Small, D. H., Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes.J. Neurochem., 84, 471–479 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Tan, Z. S., Seshadri, S., and Beiser, A., Plasma total cholesterol level as a risk factor for Alzheimer’s disease: the Framingham study.Arch. Intern. Med., 163, 1053–1057 (2003).

    Article  PubMed  CAS  Google Scholar 

  • Wahrle, S., Das, P., and Nyborg, A. C., Cholesterol-dependent g-secretase activity in buoyant cholesterol-rich membrane microdomains.Neurobiol. Dis., 9, 11–23 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Wellington, C. L., Cholesterol at the crossroads: Alzheimer’s disease and lipid metabolism.Clin. Genet., 66, 1–16 (2004).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jin Tae Hong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nguyen, H.N., Son, D.J., Lee, J.W. et al. Mutant presenilin 2 causes abnormality in the brain lipid profile in the development of Alzheimer’s disease. Arch Pharm Res 29, 884–889 (2006). https://doi.org/10.1007/BF02973910

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02973910

Key words

Navigation